Global Multicancer Screening Market by Product (AI and Machine Learning-Based Platforms, Blood-Based Tests, Breath Analysis Tests), Test Type (In-vitro diagnostics, Laboratory Developed Tests), Technology, Cancer Type, End User - Forecast 2024-2030- Product Image

Sale

Global Multicancer Screening Market by Product (AI and Machine Learning-Based Platforms, Blood-Based Tests, Breath Analysis Tests), Test Type (In-vitro diagnostics, Laboratory Developed Tests), Technology, Cancer Type, End User - Forecast 2024-2030

Report
192 Pages
May 2024
Region: Global
360iResearch™
ID: 5925117

UP TO €648EUR$675USD£558GBP OFF until Dec 31^st 2024

The Multicancer Screening Market size was estimated at USD 1.40 billion in 2023, USD 1.53 billion in 2024, and is expected to grow at a CAGR of 9.90% to reach USD 2.72 billion by 2030.

The multicancer screening is revolutionary in medical research associated with oncology, leveraging cutting-edge technologies such as liquid biopsies, genetic testing, and artificial intelligence (AI) to facilitate the early detection of various cancers, including lung, breast, colorectal, and prostate. The significance of this screening method is underscored by its potential to enhance patient outcomes through the early identification of cancer, enabling timely and more efficacious treatment options.

Multicancer screening technologies promise revolutionary improvements in patient diagnostics and screening, providing healthcare systems, research entities, and consumers with tools that can lead to early interventions and significantly better health results. The adoption of these technologies is fueled by advancements in genomics and imaging, a rising global cancer incidence, and intensifying awareness of early detection benefits, further supported by governmental policies and funding measures. Opportunities for innovation are abundant, particularly in refining AI applications and liquid biopsy methods to heighten screening precision while reducing invasive procedures, seeking to align with the market's objective of improving survival rates and quality of life for patients. However, the restraints include the elevated costs associated with advanced technology development, risks of diagnostic inaccuracies, and intricate regulatory landscapes, alongside ethical and privacy dilemmas linked to genetic testing. The prioritization of cost-effective, accurate, and universally accessible screening solutions emerges as vital in overcoming these limitations. Fostering strategic partnerships among technology developers, healthcare practitioners, and regulatory authorities is crucial for unlocking the full potential of multicancer screening, setting the stage for substantial growth in the market, and a pronounced impact on global health outcomes.

Regional Insights

In the United States, the multicancer screening market is driven by significant healthcare R&D investments and a focus on early detection. This trend is supported by innovations in liquid biopsy and AI-driven diagnostics, with the National Cancer Institute's Cancer Moonshot initiative underscoring a commitment to reducing cancer incidence and mortality. Consumer preferences are toward tests that are insurance-covered or offer substantial predictive accuracy. Canada adopts a similar proactive stance in cancer screening, emphasizing integration within its public healthcare system to enhance accessibility and affordability, backed by the Canadian Institutes of Health Research.

In Asia-Pacific, China's economic incline has fueled a surge in healthcare spending, fostering the adoption of AI and genetic testing innovations under the Healthy China 2030 plan. Japan prioritizes multi-cancer screening within its healthcare strategy, leveraging technological sophistication to support early detection efforts. India, while in the early stages of multicancer market development, shows promise through government initiatives such as the National Cancer Screening Program and private innovation aimed at accessible solutions. Furthermore, EU countries indicate a unified front toward healthcare innovation, with Horizon Europe funding multi-cancer research. The Middle East, particularly UAE and Saudi Arabia, is evolving its healthcare landscape to prioritize preventive care and partnerships for healthcare advancements. Africa is facing infrastructural challenges; however, it is witnessing efforts by international health organizations to develop scalable and cost-effective screening solutions.

Market Trends by Segment

Product: Improvement in early cancer detection through revolutionary innovations in ai-enhanced screening and diagnostic technologies
Test Type: In-vitro diagnostics and laboratorydeveloped tests are preferred for early cancer detection and improve patient outcomes
Technology: Significant preference toward PCR for its efficiency in early detection and accuracy
Cancer Type: Emphasizing innovation and accessibility through advancement in the multispeciality screening
End-User: Harmonizing innovation and care to navigate multi cancer screening priorities across academic, diagnostic, and healthcare sectors

Industry Insights

Market Dynamics
Market Disruption Analysis
Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis
FPNV Positioning Matrix
Market Share Analysis
Strategy Analysis and Recommendations

Recent Developments

Strategic Funding Fuels Freenome's Advancement in Early Cancer Detection Technology

Freenome garnered USD 254 million from a mixture of new and returning investors to propel the development of its pioneering multi-cancer early detection tests, leveraging its comprehensive multiomics platform. The company's cutting-edge approach combines computational biology and machine learning to craft non-invasive screening tools that promise to shift the landscape of cancer diagnosis by detecting the disease at its most treatable stages. Furthermore, collaborations with biopharma and diagnostics companies aim to extend the platform's utility to minimal residual disease testing, embodying a significant step forward in personalized healthcare and cancer management.

PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform

PanGIA Biotech announced redefining cancer diagnostics with its proprietary PanGIA Liquid Biopsy Platform. Having completed a pioneering three-year clinical study on prostate cancer detection through urine samples, the company now embarks on an ambitious venture to extend its research into multi-cancer early detection.

Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp

Exact Sciences Corp. unveiled its latest advancement, the Riskguard hereditary multi-cancer multigene panel test, in the United States. This innovative genetic screening tool utilizes a blood or saliva sample to provide a detailed patient report outlining gene-specific and familial risks associated with ten prevalent cancers: colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney, and endocrine. The test's introduction aligns with updated clinical guidelines advocating for germline mutation testing in breast cancer, marking a pivotal advancement in precision oncology.

Key Company Profiles

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include ANPAC Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Fulgent Genetics, Inc., Gene Solutions, Grail, LLC by Illumina, Inc., Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Ltd.

This research report offers invaluable insights into various crucial aspects of the Multicancer Screening Market:

Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current market size and projected growth?
Which products, segments, applications, and regions offer promising investment opportunities?
What are the prevailing technology trends and regulatory frameworks?
What is the market share and positioning of the leading vendors?
What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer disease and rising aging population
5.1.1.2. Several government initiatives promoting multicancer screening in healthcare facilities
5.1.2. Restraints
5.1.2.1. Time-consuming procedures coupled with high cost associated with multicancer screening
5.1.3. Opportunities
5.1.3.1. Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
5.1.3.2. Rising R&D activities for the development of cancer diagnostics treatment procedures
5.1.4. Challenges
5.1.4.1. Concerns associated with adequate safety and efficacy data and variability in test performance
5.2. Market Segmentation Analysis
5.2.1. Product: Improvement in early cancer detection through revolutionary innovations in ai-enhanced screening and diagnostic technologies
5.2.2. Test Type: In-vitro diagnostics and laboratorydeveloped tests are preferred for early cancer detection and improve patient outcomes
5.2.3. Technology: Significant preference toward PCR for its efficiency in early detection and accuracy
5.2.4. Cancer Type: Emphasizing innovation and accessibility through advancement in the multispeciality screening
5.2.5. End-User: Harmonizing innovation and care to navigate multi cancer screening priorities across academic, diagnostic, and healthcare sectors
5.3. Market Trend Analysis
5.3.1. Favorable regulatory approvals for multicancer screening platforms and advancements to integrate personalized strategies in cancer diagnosis across the Americas
5.3.2. Rapid digitalization of the healthcare ecosystem and government efforts to increase the accessibility of cancer care and diagnostics services in the APAC region
5.3.3. Extensive R&D activities on multicancer screening and extension of global companies in EMEA with government approvals
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Multicancer Screening Market, by Product

6.1. Introduction
6.2. AI and Machine Learning-Based Platforms
6.3. Blood-Based Tests
6.4. Breath Analysis Tests
6.5. Fecal Tests
6.6. Gene Panels/Test Panels
6.7. Imaging Tests
6.8. Saliva & Buccal Swab Test
6.9. Tissue Test
6.10. Urine-Based Tests

7. Multicancer Screening Market, by Test Type

7.1. Introduction
7.2. In-vitro diagnostics
7.3. Laboratory Developed Tests

8. Multicancer Screening Market, by Technology

8.1. Introduction
8.2. Fluorescence In-Situ Hybridization
8.3. Immunohistochemistry
8.4. Next-Generation Sequencing
8.5. Polymerase Chain Reaction

9. Multicancer Screening Market, by Cancer Type

9.1. Introduction
9.2. Brain/Nervous System
9.3. Breast & Gynecologic
9.4. Endocrine
9.5. Gastrointestinal
9.6. Genitourinary
9.7. Hematological Malignancies
9.8. Lung
9.9. Sarcoma
9.10. Skin

10. Multicancer Screening Market, by End User

10.1. Introduction
10.2. Academic & Research Institutions
10.3. Diagnostic & Clinical Laboratories
10.4. Hospitals

11. Americas Multicancer Screening Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Multicancer Screening Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Multicancer Screening Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Strategic Funding Fuels Freenome's Advancement in Early Cancer Detection Technology
14.3.2. PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform
14.3.3. Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp
14.3.4. Strategic Partnership Between SeekIn Inc. and Oncolnv to Enhance Global Cancer Detection Efforts
14.3.5. Collaboration Between AnchorDx and DiaCarta to Revolutionize Global Cancer Screening
14.3.6. Burning Rock Biotech Achieves Global Recognition with OverC Multi-Cancer Detection Blood Test
14.3.7. Elypta Attains ISO 13485:2016 Certification, Advancing GAGome-Based Multicancer Detection
14.3.8. Strategic Acquisition by Freenome Amplifies Cancer Screening Capabilities through Oncimmune Ltd's Advanced Diagnostics
14.3.9. Lucence Advances Cancer Detection with Innovative MCED Blood Test: A Strategic Unveiling in the U.S.

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio

List of Figures

FIGURE 1. MULTICANCER SCREENING MARKET RESEARCH PROCESS
FIGURE 2. MULTICANCER SCREENING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 6. MULTICANCER SCREENING MARKET DYNAMICS
FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 17. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 19. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 21. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
FIGURE 25. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2023 (USD THOUSAND)
TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2024-2030 (USD THOUSAND)
TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AI AND MACHINE LEARNING-BASED PLATFORMS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AI AND MACHINE LEARNING-BASED PLATFORMS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREATH ANALYSIS TESTS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREATH ANALYSIS TESTS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FECAL TESTS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FECAL TESTS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANELS/TEST PANELS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANELS/TEST PANELS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SALIVA & BUCCAL SWAB TEST, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SALIVA & BUCCAL SWAB TEST, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TISSUE TEST, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TISSUE TEST, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY URINE-BASED TESTS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY URINE-BASED TESTS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IN-VITRO DIAGNOSTICS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IN-VITRO DIAGNOSTICS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TESTS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TESTS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 47. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 48. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 49. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 50. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 51. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 52. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 53. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BRAIN/NERVOUS SYSTEM, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 54. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BRAIN/NERVOUS SYSTEM, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 55. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST & GYNECOLOGIC, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 56. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST & GYNECOLOGIC, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 57. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 58. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ENDOCRINE, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 59. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 60. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 61. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENITOURINARY, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 62. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENITOURINARY, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 63. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 64. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 65. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 66. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 67. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 68. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SARCOMA, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 69. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SKIN, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 70. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SKIN, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 71. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 72. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 73. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 74. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 75. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC & CLINICAL LABORATORIES, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 76. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC & CLINICAL LABORATORIES, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 77. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD THOUSAND)
TABLE 78. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD THOUSAND)
TABLE 79. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 80. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 81. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 82. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 83. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 84. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 85. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 86. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 87. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 88. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 89. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 90. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 91. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
TABLE 92. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
TABLE 93. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 94. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 95. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 96. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 97. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 98. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 99. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 100. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 101. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 102. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 103. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 104. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 105. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 106. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 107. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 108. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 109. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 110. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 111. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 112. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 113. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 114. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 115. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 116. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 117. CANADA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 118. CANADA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 119. CANADA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 120. CANADA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 121. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 122. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 123. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 124. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 125. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 126. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 127. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 128. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 129. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 130. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 131. MEXICO MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 132. MEXICO MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 133. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 134. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 135. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 136. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 137. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 138. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 139. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 140. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 141. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 142. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 143. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 144. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 145. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 146. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 147. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 148. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 149. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 150. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 151. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 152. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 153. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2023 (USD THOUSAND)
TABLE 154. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024-2030 (USD THOUSAND)
TABLE 155. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 156. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 157. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 158. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 159. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 160. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 161. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 162. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 163. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 164. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 165. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 166. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 167. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
TABLE 168. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
TABLE 169. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 170. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 171. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 172. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 173. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 174. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 175. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 176. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 177. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 178. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 179. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 180. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 181. CHINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 182. CHINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 183. CHINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 184. CHINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 185. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 186. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 187. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 188. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 189. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 190. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 191. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 192. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 193. INDIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 194. INDIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 195. INDIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 196. INDIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 197. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 198. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 199. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 200. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 201. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 202. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 203. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 204. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 205. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 206. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 207. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 208. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 209. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 210. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 211. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 212. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 213. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 214. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 215. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 216. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 217. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 218. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 219. JAPAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 220. JAPAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 221. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 222. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 223. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 224. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 225. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 226. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 227. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 228. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 229. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 230. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 231. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 232. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 233. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 234. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 235. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 236. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 237. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 238. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 239. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 240. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 241. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 242. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 243. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 244. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 245. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 246. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 247. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 248. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 249. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 250. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 251. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 252. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 253. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 254. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 255. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 256. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 257. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 258. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 259. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 260. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 261. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 262. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 263. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 264. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 265. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 266. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 267. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 268. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 269. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 270. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 271. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 272. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 273. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 274. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 275. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 276. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 277. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 278. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 279. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 280. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 281. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 282. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 283. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 284. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 285. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 286. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 287. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 288. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 289. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 290. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 291. THAILAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 292. THAILAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 293. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 294. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 295. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 296. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 297. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 298. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 299. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 300. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 301. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 302. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 303. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 304. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 305. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 306. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 307. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 308. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 309. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 310. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 311. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 312. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD THOUSAND)
TABLE 321. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD THOUSAND)
TABLE 322. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD THOUSAND)
TABLE 323. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2023 (USD THOUSAND)
TABLE 324. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024-2030 (USD THOUSAND)
TABLE 325. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
TABLE 326. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
TABLE 327. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2023 (USD THOUSAND)
TABLE 328. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2024-2030 (USD THOUSAND)
TABLE 329. DENMARK MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2023 (USD THOUSAND)
TABLE 330. DENMARK MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2024-2030 (USD THOUSAND)
TABLE 331. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2023 (USD THOUSAND)
TABLE 332. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024-2030 (USD THOUSAND)
TABLE 333. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD THOUSAND)
TABLE 334. DENMARK MULTICANCER SCREENING MARKET SIZE, BY T

Companies Mentioned

ANPAC Bio-Medical Science Co., Ltd.
Burning Rock Biotech Limited
Caris Life Sciences
Coyne Medical Ltd.
Delfi Diagnostics, Inc.
Elypta AB
EpiCypher, Inc.
Epigenomics AG
Exact Sciences Corporation
Foundation Medicine, Inc.
Freenome Holdings, Inc.
Fulgent Genetics, Inc.
Gene Solutions
Grail, LLC by Illumina, Inc.
Guangzhou AnchorDx Medical Co., Ltd.
Guardant Health, Inc.
Invitae Corporation
Laboratory Corporation of America Holdings
Lucence Health Inc.
Micronoma, Inc.
MiRXES Pte Ltd.
Myriad Genetics, Inc.
Natera, Inc.
Naveris, Inc.
NeoGenomics Laboratories
OneTest
Siemens Healthineers AG
StageZero Life Sciences. Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	192
Published	May 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 1.53 Billion
Forecasted Market Value ( USD ) by 2030	$ 2.72 Billion
Compound Annual Growth Rate	9.9%
Regions Covered	Global
No. of Companies Mentioned	28

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Month

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3237EUR$3,374USD£2,788GBP €3597EUR$3,749USD£3,098GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4101EUR$4,274USD£3,532GBP €4557EUR$4,749USD£3,925GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4964EUR$5,174USD£4,276GBP €5516EUR$5,749USD£4,751GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5828EUR$6,074USD£5,020GBP €6476EUR$6,749USD£5,577GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Month	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one month.	This is an enterprise license, allowing all employees within your organization access to the product.	€8395EUR$8,749USD£7,230GBP

Regional Insights

Market Trends by Segment

Industry Insights

Recent Developments

Strategic Funding Fuels Freenome's Advancement in Early Cancer Detection Technology

PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform

Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp

Key Company Profiles

This research report offers invaluable insights into various crucial aspects of the Multicancer Screening Market:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Liver Cancer Diagnostics Market by Test Type (Biopsy, Endoscopy, Imaging), End User (Academic & Research Institutes, Hospitals & Diagnostic Laboratories, Pharmaceutical & CRO Laboratories) - Forecast 2024-2030

Direct-to-consumer (DTC) Laboratory Testing Market by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, COVID, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood) - Global Forecast to 2030

Global Tissue Diagnostics Market by Product (Accessories, Consumables, Instruments), Technology (Digital Pathology & Workflow, Immunohistochemistry, In Situ Hybridization), Indications, End-User - Forecast 2024-2030

Global Liver Disease Diagnostics Market Size, Share & Trends Analysis Report by Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy, Others), End-use (Hospitals, Laboratories, Others), Region, and Segment Forecasts, 2023-2030

Global Diagnostics Labs Market Outlook, 2029